Among eligible respondents, 48.9% (95% CI 48.1%–49.8%) reported any prior SDM regarding prostate cancer screening, with 21.0% (95% 20.3%–21.6%) of respondents reporting hearing about both the advantages and disadvantages of the PSA test, 26.7% (95% CI 25.9%–27.4%) the advantages only, and 1.3% (95% CI 1.1%–1.5%) the disadvantages only. Here, KLK3 is linked to prostate cancer.